Detailed demographics and disease characteristics by patient
| ID . | Age (y) . | Sex . | Prior lines . | ECOG . | MM type . | BMPC (%) . | FISH . | κκLC (mg/L) . | λλLC (mg/L) . | FLC ratio . | M protein (g/dL) . | Bridging . | CAR T-cell product . | CRS grade . | ICANS grade . | Best response by IMWG . | Sustained MRD-neg . | Time to best response (d) . | Time to progression (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MM1 | 55 | F | 6 | 0 | IgG kappa | na | Hyperploid, 13q- | 139 | 2 | 69.5 | 3.6 | Y | bb2121 | 2 | 0 | sCR MRDneg | N | 231 | 351 |
| MM2 | 66 | F | 12 | 1 | IgG lambda | 50 | Normal | 1 | 318 | 0.03 | 4 | N | bb2121 | 1 | 1 | PR | N | 93 | 232 |
| MM3 | 63 | F | 10 | 0 | IgG kappa | 50 | 1q21 amp | 1228 | 2 | 614 | 1.9 | Y | bb2121 | 1 | 0 | PR | N | 14 | 87 |
| MM4 | 61 | M | 5 | 0 | IgG kappa | 95 | del 17p, 1q21 amp, t(11:14) | 1497 | 2 | 748.5 | 5.2 | N | bb2121 | 2 | 0 | sCR MRDneg | Y | 270 | 335 |
| MM5 | 67 | F | 8 | 0 | IgG kappa | na | t(14:16); 1q21 amo, 13q- | 942 | 2 | 471 | 2.7 | Y | bb21217 | 1 | 1 | PR | N | 28 | 177 |
| MM6 | 71 | F | 1 | 0 | IgG lambda | 5 | Normal | 10.4 | 8 | 0.77 | 0.3 | N | bb2121 | 1 | 0 | sCR MRDneg | Y | 106 | >1000 |
| MM7 | 71 | M | 6 | 1 | IgG kappa | 80 | 1q21 amp, del 17p | 652 | 2 | 326 | 0 | Y | JCARH125 | 1 | 1 | sCR MRDneg | N | 30 | 165 |
| MM8 | 51 | M | 7 | 1 | IgG kappa | 50 | Tetraploidy, t(11:14) | 155 | 2 | 77.5 | 4 | Y | JCARH125 | 2 | 2 | sCR MRDneg | N | 331 | 331 |
| MM9 | 73 | M | 5 | 1 | IgG kappa | 40 | 1q21 amp | 1.5 | 2 | 0.75 | 1.2 | N | JCARH125 | 2 | 0 | PR | N | 21 | 338 |
| MM10 | 69 | F | 5 | 0 | IgG kappa | 10 | 1q21 amp, del 17p | 121 | 2 | 60.5 | 4.3 | Y | JCARH125 | 1 | 1 | VGPR MRDneg | N | 87 | 175 |
| MM11 | 74 | F | 4 | 1 | IgG kappa | 50 | 1q21 amp | 671 | 2.2 | 305 | 1.4 | N | JCARH125 | 0 | 0 | sCR MRDneg | Y | 363 | 1098 |
| MM12 | 52 | F | 7 | 1 | IgG kappa | 5 | 1q21 amp, del 17p | 144 | 2 | 72 | 2 | Y | JCARH125 | 2 | 0 | sCR MRDneg | Y | 221 | >1000 |
| MM13 | 68 | F | 6 | 0 | IgA kappa | 50 | 1q21 amp, del 17p | 717 | 2 | 358.5 | 0 | Y | JCARH125 | 0 | 0 | sCR MRDneg | Y | 27 | 264 |
| MM14 | 34 | M | 6 | 0 | LC kappa | 95 | 1q21 amp, 13q- | 11054 | 2 | 5527 | neg | N | JCARH125 | 2 | 0 | sCR MRDneg | N | 17 | 148 |
| MM15 | 55 | M | 5 | 0 | LC kappa | 70 | t(11:14), del 17q | 1060 | 2 | 530 | neg | N | JCARH125 | 1 | 0 | sCR MRDneg | N | 28 | 125 |
| ID . | Age (y) . | Sex . | Prior lines . | ECOG . | MM type . | BMPC (%) . | FISH . | κκLC (mg/L) . | λλLC (mg/L) . | FLC ratio . | M protein (g/dL) . | Bridging . | CAR T-cell product . | CRS grade . | ICANS grade . | Best response by IMWG . | Sustained MRD-neg . | Time to best response (d) . | Time to progression (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MM1 | 55 | F | 6 | 0 | IgG kappa | na | Hyperploid, 13q- | 139 | 2 | 69.5 | 3.6 | Y | bb2121 | 2 | 0 | sCR MRDneg | N | 231 | 351 |
| MM2 | 66 | F | 12 | 1 | IgG lambda | 50 | Normal | 1 | 318 | 0.03 | 4 | N | bb2121 | 1 | 1 | PR | N | 93 | 232 |
| MM3 | 63 | F | 10 | 0 | IgG kappa | 50 | 1q21 amp | 1228 | 2 | 614 | 1.9 | Y | bb2121 | 1 | 0 | PR | N | 14 | 87 |
| MM4 | 61 | M | 5 | 0 | IgG kappa | 95 | del 17p, 1q21 amp, t(11:14) | 1497 | 2 | 748.5 | 5.2 | N | bb2121 | 2 | 0 | sCR MRDneg | Y | 270 | 335 |
| MM5 | 67 | F | 8 | 0 | IgG kappa | na | t(14:16); 1q21 amo, 13q- | 942 | 2 | 471 | 2.7 | Y | bb21217 | 1 | 1 | PR | N | 28 | 177 |
| MM6 | 71 | F | 1 | 0 | IgG lambda | 5 | Normal | 10.4 | 8 | 0.77 | 0.3 | N | bb2121 | 1 | 0 | sCR MRDneg | Y | 106 | >1000 |
| MM7 | 71 | M | 6 | 1 | IgG kappa | 80 | 1q21 amp, del 17p | 652 | 2 | 326 | 0 | Y | JCARH125 | 1 | 1 | sCR MRDneg | N | 30 | 165 |
| MM8 | 51 | M | 7 | 1 | IgG kappa | 50 | Tetraploidy, t(11:14) | 155 | 2 | 77.5 | 4 | Y | JCARH125 | 2 | 2 | sCR MRDneg | N | 331 | 331 |
| MM9 | 73 | M | 5 | 1 | IgG kappa | 40 | 1q21 amp | 1.5 | 2 | 0.75 | 1.2 | N | JCARH125 | 2 | 0 | PR | N | 21 | 338 |
| MM10 | 69 | F | 5 | 0 | IgG kappa | 10 | 1q21 amp, del 17p | 121 | 2 | 60.5 | 4.3 | Y | JCARH125 | 1 | 1 | VGPR MRDneg | N | 87 | 175 |
| MM11 | 74 | F | 4 | 1 | IgG kappa | 50 | 1q21 amp | 671 | 2.2 | 305 | 1.4 | N | JCARH125 | 0 | 0 | sCR MRDneg | Y | 363 | 1098 |
| MM12 | 52 | F | 7 | 1 | IgG kappa | 5 | 1q21 amp, del 17p | 144 | 2 | 72 | 2 | Y | JCARH125 | 2 | 0 | sCR MRDneg | Y | 221 | >1000 |
| MM13 | 68 | F | 6 | 0 | IgA kappa | 50 | 1q21 amp, del 17p | 717 | 2 | 358.5 | 0 | Y | JCARH125 | 0 | 0 | sCR MRDneg | Y | 27 | 264 |
| MM14 | 34 | M | 6 | 0 | LC kappa | 95 | 1q21 amp, 13q- | 11054 | 2 | 5527 | neg | N | JCARH125 | 2 | 0 | sCR MRDneg | N | 17 | 148 |
| MM15 | 55 | M | 5 | 0 | LC kappa | 70 | t(11:14), del 17q | 1060 | 2 | 530 | neg | N | JCARH125 | 1 | 0 | sCR MRDneg | N | 28 | 125 |
BMPC, bone marrow plasma cells; CRS, cytokine release syndrome; ECOG, Eastern Cooperative Oncology Group performance status; FISH, fluorescent in situ hybridization; F, female; FLC, serum free light chain; ICANS, immune effector cell-associated neurotoxicity syndrome; IgG, immunoglobulin G; IMWG, International Myeloma Working Group; LC, light chain; M, male; MRD, minimal residual disease; N, no; na, not available; neg, negative; PR, partial response; sCR, stringent complete response; VGPR, very good partial response; Y, yes.
Sustained MRD negativity defined at MRD negativity at D28, D90 and D180.